Development asset linked to Duke University in public FDA and regional records. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
pharma · Metastatic Breast Cancer · Talaromycosis
Duke University
Duke University drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 2
- Drugs
- 5
- Patents
- 0
Duke University pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Duke University drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
amikacin
Antiinfectives for systemic use (J01)Antiinfectives for systemic use (J01) compound in Duke University's portfolio.
-
US regulatory status: approved. Molecular target: Ergosterol.
- Target
- Ergosterol
- Mechanism
- Ergosterol sequestering agent
-
Development asset linked to Duke University in public FDA and regional records.
-
Development asset linked to Duke University in public FDA and regional records. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor